Professor Peter Sandercock

Emeritus Professor of Medical Neurology

Background

Studied Medicine at the University of Oxford, and undertook my postgraduate clinical training in Stoke-on-Trent, Manchester, Oxford and Liverpool, followed by a visiting academic fellowship at McMaster University Canada. My initial research was on the epidemiology of stroke in Oxfordshire, and in clinical trials of stroke prevention.

I set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke from 1991-1997.19,453 patients were recruited within 48 hours of stroke onset from 467 hospitals in 37 countries. I am the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with 3035 patients. 

My main academic activities are teaching, preparing educational maetrials on stroke for the World Stroke Organisation and contribting to clinical trial research governance though membership or Chairmanship of Trial Steering Committes and Trial data Monitoring Committees.

Qualifications

MA, DM

Responsibilities & affiliations

Member of the Board of Directors World Stroke Organisation.  Commissioning Editor for the World Stroke Academy.  

Research summary

My research covers treatment and prevention of stroke and seeks to identify which interventions are effective, which are not, and which are worth testing in large scale trials. I now spend much of my time either supporting fellow scientist in doing their own clinical trials, looking to improve patient care or teaching and training young researchers in how to do this type of scientific work.

The main focus of my present research is to further explore the effects of intravenous thrombolytic therapy in acute ischaemic stroke in the IST-3 study and other similar trials.

Research activities

View all 34 activities on Research Explorer

View all 233 publications on Research Explorer